Cao Jiayi's case of accidentally taking banned drugs for a cold has landed, and he has received a one-year ban from the tennis anti-drug program

In response to the case of Chinese Taipei professional women's tennis player Cao Jiayi who accidentally took banned drugs for a cold in January this year, the International Tennis Integrity Agency (ITIA) confirmed on the 18th that she has received a 12-month ban from the Tennis Anti-Banned Drug Program (TADP).

Cao Jiayi

Chinese Taipei's Cao Chia-yi, who participated in the 2024 Paris Olympics, received a notice from ITIA that he had been temporarily suspended from March 1 because he tested positive for the banned drug Methylephedrine during the competition in Auckland in January 2025. According to a press release following the ITIA investigation, methylephedrine is a specific substance under the TADP rules and must be subject to a valid therapeutic use exemption before it can be used; Cao Jiayi explained that it was caused by taking Pabron Gold A comprehensive cold medicine purchased from a pharmacy at Tokyo Airport in Japan, and the ITIA finally determined that this violation was not intentional, and decided to suspend the game for a reasonable period of time with reference to the precedents of similar cases.

ITIA said that Cao Jiayi has agreed to accept the verdict and will not participate in, coach or attend any tennis tournament authorized and recognized by international tennis institutions (ITF, ATP, WTA, four Grand Slam tournaments) or any national (regional) association until February 28, 2026.